Loading…
← CockpitCompetitor Analysis › 688276.SS Changchun BCHT Biotechnology Co. Class AOpen in the cockpit ↗

Changchun BCHT Biotechnology Co. Class A688276.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese vaccine and biologics maker based in Changchun, with a focus on rabies vaccine and blood-plasma products.

Momentum leader 92
Mkt cap
$992M
US dollars, full cap
Free float
28%
of shares outstanding
$/day
$7.48M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-12.3 pp
WACC 10.1%
Hurdle
n/a
no reverse DCF
Next earnings
120 days
18 Mar 2027
Close · CNYCN¥17.15
1D+14.6%
1W+5.3%
1M+3.9%
3M+7.5%
6M-1.9%
YTD-9.1%
1Y-22.1%
ATR %4.5%
52w lowhigh29.9% off high

What Changchun BCHT Biotechnology does

Chinese vaccine and biologics maker based in Changchun, with a focus on rabies vaccine and blood-plasma products.

Products and services

  • Human rabies vaccine
  • Plasma-derived products

Customers

  • CDC/vaccination centers
  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Vaccines & plasma products

What could go right

  • Rabies vaccination demand

What could go wrong

  • Vaccine pricing pressure
  • Small scale vs national leaders

Moat: narrow (regulatory licence). Licensed rabies-vaccine and plasma production base, competing with larger national players.

Headquarters: Changchun, China · Employees: 1,252

Named competitors

Changchun BCHT Biotechnology at a glance

Size Changchun BCHT Biotechnology (688276.SS) is a China Health Care company (Biotechnology) with a market value of $992M, the 2172nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.15 on 18 Nov 2026.

Performance Over six months the shares fell 1.9%, against -15.1% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue grew 2.5% over the last twelve months (peer median +7.8%); the operating margin is -28.8% (peer median -18.3%).

Valuation It trades at 9.9× enterprise value to sales against a peer median of 5.9× (4th most expensive of 15).

Capital Return on invested capital runs 12.3 points below its cost of capital (10.1% WACC).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026688276.SS 99Peer median 85
Six months, rebased to 100: Changchun BCHT Biotechnology against the median of its 20 peers (local-currency closes).

Changchun BCHT Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥694MCN¥603MCN¥1.22BCN¥1.82BCN¥1.07B
Revenue growth—-51%-33%+70%—
Gross profitCN¥530MCN¥292MCN¥1.01BCN¥1.60BCN¥904M
EBITDAn/a-CN¥162MCN¥364MCN¥641MCN¥237M
Net income-CN¥200M-CN¥263MCN¥232MCN¥501MCN¥182M
Free cash flow-CN¥111M-CN¥180M-CN¥138M-CN¥278M-CN¥292M
Capital expenditureCN¥403MCN¥406MCN¥542MCN¥471MCN¥291M
Total debtCN¥513MCN¥265MCN¥103MCN¥20.5MCN¥0

Quarterly statements and history in the cockpit →

Changchun BCHT Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%SGPINBXANRO3004820020309606600195JBIO688253ODTX2160VOR4587VSTMCMPSOXBAKUMSMGTX688276.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Changchun BCHT Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×200×400×INBX300482002030ODTXVSTMMGTX688276.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Changchun BCHT Biotechnology is the large dot.

Changchun BCHT Biotechnology competitors and peer comparison

Head to head with its named competitors (688276.SS vs 688739.SS vs 002007.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Changchun BCHT Biotechnology 688276.SS$992M-2%+2%-29%9.9×n/a
Liaoning Chengda Biotechnology 688739.SS$1.22B-14%-9%0%2.2×6.6%
Hualan Biological Engineering 002007.SZ$3.20B-17%-11%17%5.3×15.8%

How Changchun BCHT Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Changchun BCHT Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure688276.SSPeer medianRank in peer set
1-month return+3.9%-8.8%4th highest of 21
6-month return-1.9%-15.1%7th highest of 20
Distance from 52-week high-29.9%-40.8%3rd highest of 21
Revenue growth (TTM)+2.5%+7.8%8th highest of 15
Operating margin-28.8%-18.3%6th lowest of 15
EV / Sales9.9×5.9×4th most expensive of 15
ROIC minus cost of capital-12.3 pp-8.9 pp5th lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%4.2×9.2%+2.3%
GNI 2160.TJapan$903M-25%+44%-21%6.2×n/an/a
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a
Verastem VSTMUnited States$866M+66%+650%-194%8.2×n/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%4.1×n/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a

Questions

Who are Changchun BCHT Biotechnology's main competitors?
Named competitors: Liaoning Chengda Biotechnology (688739.SS), Hualan Biological Engineering (002007.SZ). The cockpit's measured peer set (industry) also includes SpyGlass Pharma (SGP), Inhibrx Biosciences (INBX), Alto Neuroscience (ANRO), Guangzhou Wondfo Biotech (300482.SZ), Daan Gene (002030.SZ), Duality Biotherapeutics (9606.HK).
Is Changchun BCHT Biotechnology expensive compared with its peers?
On ev / sales it trades at 9.9× against a peer median of 5.9×, 4th most expensive of 15 in its peer set.
How has Changchun BCHT Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -1.9% against -15.1% for the median peer; over one year -22.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.